KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Receivables - Accured (2020 - 2024)

Vir Biotechnology's Revenue - Other history spans 6 years, with the latest figure at $14.3 million for Q1 2023.

  • For Q1 2023, Revenue - Other rose 450.0% year-over-year to $14.3 million; the TTM value through Mar 2023 reached $38.1 million, up 277.23%, while the annual FY2022 figure was $26.4 million, 221.95% up from the prior year.
  • Receivables - Accured for Q1 2024 was $5.7 million at Vir Biotechnology, up from $4.0 million in the prior quarter.
  • Across five years, Receivables - Accured topped out at $5.7 million in Q1 2024 and bottomed at $600000.0 in Q2 2021.
  • The 5-year median for Receivables - Accured is $1.8 million (2022), against an average of $2.1 million.
  • The largest YoY upside for Revenue - Other was 880.0% in 2020 against a maximum downside of 1300.0% in 2020.
  • A 5-year view of Revenue - Other shows it stood at $2.8 million in 2019, then skyrocketed by 207.14% to $8.6 million in 2020, then tumbled by 66.93% to $2.8 million in 2021, then surged by 568.07% to $19.0 million in 2022, then fell by 24.74% to $14.3 million in 2023.
  • Per Business Quant, the three most recent readings for VIR's Revenue - Other are $14.3 million (Q1 2023), $19.0 million (Q4 2022), and $2.7 million (Q3 2022).